 |
|
Influenza
Adam Cifu, MD;
Wendy Levinson, MD
JAMA. 2000;284:2847-2849.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
Influenza is a highly morbid illness affecting 10% to 20% of the US population and accounting for 110,000 hospitalizations and 10,000 to 40,000 deaths yearly.1-3 In addition to the burden of illness during the influenza season, there is also the risk of more severe influenza pandemics. In this article, we summarize some of the advances that will affect the management of patients who are either at risk of influenza or present with clinical disease.
Prevention
Vaccination
Inactivated intramuscular vaccines are developed yearly to match the predicted strains of influenza in the coming season. These are available as whole virus, split product, or neuraminidase/hemagglutinin subunit vaccines. In recent years, a trivalent vaccine that includes 2 strains of influenza A (H1N1, H3N2) and 1 strain of influenza B has been used. The optimal timing for vaccination in the northern hemisphere is October through mid November and recommendations concerning . . . [Full Text of this Article] Chemoprophylaxis
Laboratory Diagnosis
Treatment
Future Directions
Author Affiliation: Department of Medicine, University of Chicago, Chicago, Ill.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
December 13, 2000
JAMA. 2000;284(22):2947-2948.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Influenza in long-term care facilities: Preventable, detectable, treatable
Mossad
Cleveland Clinic Journal of Medicine 2009;76:513-521.
ABSTRACT
| FULL TEXT
Efficacy of the Influenza Vaccine in Patients with Malignant Lymphoma
Mazza et al.
Clin Med Res 2005;3:214-220.
ABSTRACT
| FULL TEXT
|
